

APR 22 2010

PTO/SB/81A (12-08)

Approved for use through 11/30/2011. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>PATENT - POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Patent Number	7,524,854
	Issue Date	04/28/2009
	First Named Inventor	Greiveldinger-Poenaru
	Title	Benzofuran Derivatives and Their Use in the Treatment of Microbial Infections
	Attorney Docket Number	10-171

I hereby revoke all previous powers of attorney given in the above-identified patent.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) with respect to the patent identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

20306

OR

☐ I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) with respect to the patent identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified patent to:

☒ The address associated with the above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Inventor, having ownership of the patent.

OR

☒ Patent owner.

Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on

SIGNATURE of Inventor or Patent Owner

Signature

Date

Name

Telephone

Title and Company

**NOTE:** Signatures of all the inventors or patent owners of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.☒ \*Total of 2 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
www.FormsWorkflow.com

RECEIVED  
CENTRAL FAX CENTER

003

APR 22 2010

PTO/SB/81A (12-08)

Approved for use through 11/30/2011. OMB 0651-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>PATENT - POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Patent Number	7,524,854
	Issue Date	04/28/2009
	First Named Inventor	Greiveldinger-Poenaru
	Title	Benzofuran Derivatives and Their Use in the Treatment of Microbial Infections
	Attorney Docket Number	10-171

I hereby revoke all previous powers of attorney given in the above-identified patent.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) with respect to the patent identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

20306

OR

☐ I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) with respect to the patent identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified patent to:

☒ The address associated with the above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

☐ Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Inventor, having ownership of the patent.

OR

☒ Patent owner.

Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on

SIGNATURE of Inventor or Patent Owner

Signature	<i>J. Synnes Hansen</i>	Date	1 Mar 2010
Name	Jakob Synnes Hansen	Telephone	41 61 485 2034
Title and Company	Chief Financial Officer of Evolve Holding SA		

NOTE: Signatures of all the inventors or patent owners of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ Total of 2 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
www.FormsWorld.com

PTO/SB/96 (07-08)

Approved for use through 07/31/2012. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Greiveldinger-Poenaru et al.Application No./Patent No.: 7,524,854 Filed/Issue Date: 04/28/2009Entitled: BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONSEVOLVA SA, a private limited Swiss company

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title and interest in  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: inventors To: Arpida AGThe document was recorded in the United States Patent and Trademark Office at Reel 022087, Frame 0659, or for which a copy thereof is attached.2. From: Arpida AG To: Evolve SA

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

April 21, 2010

Date

Emily Miao, Reg. No. 35285

Attorney of record

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
www.FirmaWorkflow.com

## English Language Translation

## Commercial Register of the Canton of Basel-Landschaft – Main Register

Company No.	Legal Nature	Entry	Deletion	Carryover from: to:	I
CH-280.3.000.550-0	Aktiengesellschaft	August 18, 1997			1

All entries. [E = Entry, D = Deletion]

E	D	Company	Ref	Headquarters
1		Arpida	1	Münchenstein
2		ARPIDA AG	20	Reinach BL
2	32	(ARPIDA SA) (ARPIDA LTD)		
32		Evolva Holding SA		
32		(Evolva Holding AG) (Evolva Holding LTD)		

Ref	Share Capital (CHF)	Paid-Up Capital (CHF)	Share Division	Ref	Company Address
1	100,000.	100,000.	10,000 registered shares at CHF 10	1	Dammstrasse 36
2	336,000	336,000	10,000 registered shares at CHF 10 and 23,600 registered shares at CHF 10 (preferred shares)	20	4142 Münchenstein
6	463,350.	463,350.	10,000 registered shares at CHF 10 and 36,335 registered shares at CHF 10 (preferred shares)		Duggingerstrasse 23
7	466,600	466,600.	10,225 registered shares at CHF 10 and 36,335 registered shares at CHF 10 (preferred shares)		4153 Reinbach
8	1,022,170	1,022,170	10,225 registered shares at CHF 10 36,335 registered shares at CHF 10 (preferred shares-A) and 55,557 registered shares at CHF 10 (preferred shares-B)		
12	1,651,640	1,651,640	10,225 registered shares at CHF 10 36,335 registered shares at CHF 10 (preferred shares-A), 55,557 registered shares at CHF 10 (preferred shares-B) and 62,947 registered shares at CHF 10 (preferred shares-C)		
13			516,350 registered shares at CHF 0.20 1,816,750 registered shares at CHF 0.20 (preferred shares-A)		
			2,777,850 registered shares at CHF 0.20 (preferred shares-B) and 3,147,350 registered shares at CHF 0.20 (preferred shares-C)		
14	1,800,115.80	1,800,115.80	516,350 registered shares at CHF 0.20 1,816,750 registered shares at CHF 0.20 (preferred shares-A)		
			2,777,850 registered shares at CHF 0.20 (preferred shares-B) and 3,934,720 registered shares at CHF 0.20 (preferred shares-C)		
15	2,194,391.80	2,194,391.80	577,600 registered shares at CHF 0.20 1,816,750 registered shares at CHF 0.20 (preferred shares-A)		
			2,777,850 registered shares at CHF 0.20 (preferred shares-B) and 5,799,750 registered shares at CHF 0.20 (preferred shares-C)		
18	3,274,391.80	3,274,391.80	16,371,050 registered shares at CHF 0.20		
22	3,614,391.80	3,614,391.80	18,071,050 registered shares at CHF 0.20		
23	3,778,648.40	3,778,648.40	18,882,223 registered shares at CHF 0.20		
25	3,787,310.40	3,787,310.40	18,996,052 registered shares at CHF 0.20		
27	4,218,820.80	4,218,820.80	21,094,104 registered shares at CHF 0.20		
32	27,786,118.80	27,786,118.80	138,930,594 registered shares at CHF 0.20		
Ref	PS Capital (CHF)	Paid-Up Capital (CHF)	Participation Certificates		

E	D	Purpose	Ref	Postal Address
1	32	Research and development of medications, their marketing and all related activities.		Postfach 8010 Zurich
32		The purpose of the company is the holding of ownership interests and the research and development of medications, their marketing, and related activities. The company can conduct any transactions directly or indirectly related to its purpose or to its investment of its funds. The company can establish branches within and outside the country, own shares of other companies, or merge with them. The company can acquire, hold, and sell real estate.		

## Commercial Register of the Canton of Basel-Landschaft – Main Register

CH-280.3.000.555-0	Evolve Holding SA	Reinach BL	2
--------------------	-------------------	------------	---

All entries.

E	D	Remarks	Ref	Statute Date
1	8	The company communicates with shareholders by letter or by publication in the SHAB (Swiss Commercial Register Office Gazette). The statutes limit the ability to transfer registered shares.	1	7/23/97
1			2	7/23/98
			6	12/8/99
2	3	Preferred shares grant privileges with respect to proceeds of liquidation according to the statutes.	7	6/26/00
			8	9/20/00
3	8	Preferred shares grant privileges with respect to proceeds of liquidation and with respect to new shares according to the statutes.	8	9/28/00
			12	4/6/04
8	18	The company communicates with shareholders by registered letter.	12	5/5/04
			13	7/16/04
			14	9/22/04
8	12	Preferred shares A and B grant privileges with respect to proceeds of liquidation and with respect to new shares according to the statutes.	15	10/13/04
			17	4/8/05
12	18	Preferred shares A, B, and C grant privileges with respect to proceeds of liquidation and with respect to new shares according to the statutes.	18	4/8/05
			18	5/3/05
18		The company communicates with shareholders by publication in the SHAB.	20	7/19/06
			22	3/22/07
27		Approved increase in capital to the extent of CHF 111,610.40 and conditional increase in capital to the extent of CHF 111,610.40.	23	3/22/07
			24	5/8/07
32		With its decision of November 26, 2009, the general meeting introduced into the statutes a provisional capital increase and an approved capital increase according to designated transfer.	25	8/10/07
			27	4/1/08
			28	5/7/08
			32	11/26/09
			32	12/11/09

E	D	Special Circumstances	Ref	Where Published
1	2	Planned matter of acquisition: After the founding, the company plans to acquire a patent relating to the identification and development of inhibitors of the bacterial phosphotransferase system (PTS) as an antibacterial compound and/or the rights and duties arising from a licensing contract pertaining to the development of the antibacterial compound K-1 at a price of no more than CHF 75,000.	1	SHAB
2		In realization of the intention, expressed at the time of the founding on July 23, 1997, the company acquires a patent pertaining to the identification and development of inhibitors of the bacterial phosphotransferase system (PTS) as an antibacterial compound and/or the rights and duties arising from a licensing contract pertaining to the development of the antibacterial compound K-1 at a price of CHF 186,000.		
15		Investment in kind: As part of the capital increase of October 13, 2004 and according to the investment in kind contracts of October 8, 11, 12, and 13, 2004, the company acquires a total of 4,311,583 registered shares at DKK 1.00 of "Combio A/S" in Copenhagen (Denmark), for which 1,865,030 registered shares are issued at CHF 0.20 (preferred shares C).		
25		Investment in kind: As part of the capital increase of August 10, 2007 and according to the investment in kind contracts of August 10, 2007, the company acquires 108,751 registered shares at CHF 1.00 and 200,000 registered shares A at CHF 1.00 (preferred shares) of "TLT Medical Ltd" in Reinach BL (CH-280.3.006.432-0) at the price of CHF 2,018,252.20, for which 52,820 registered shares are issued at CHF 0.20 and CHF 2,007,688.20 are credited as to the reserves. Upon fulfillment of certain conditions, additional payments are due to the investors in a maximum amount of CHF 55,000,000.		
32		Investment in kind: As part of the regular capital increase of December 11, 2009 and according to the investment in kind contract of December 11, 2009, the company acquires a total of 318,477 registered shares at CHF 20.00 of "Evolve AG" in Albstadt (CH-170.3.027.314-5), for which 117,836,490 registered shares at CHF 0.20 are issued.		

E	D	Subsidiary	E	D	Subsidiary	E	D	Subsidiary	E	D	Subsidiary

## Commercial Register of the Canton of Basel-Landschaft- Main Register

CH-280.3.000.555-0	Evohta Holding SA	Reinach BL	3
--------------------	-------------------	------------	---

All entries.

Co de	Ref	TR No.	TR Date	SHAB Date	SHAB Date	Page	Co de	Ref	TR No.	TR Date	SHAB Date	SHAB Date	Page
----------	-----	-----------	------------	--------------	--------------	------	----------	-----	-----------	------------	--------------	--------------	------

Ref	Ref	TR No.	TR Date	SHAB Date	SHAB Date	Page	Co de	Ref	TR No.	TR Date	SHAB Date	SHAB Date	Page
1	1	1	1	1	1	1	1	1	1	1	1	1	1
2	2	2	2	2	2	2	2	2	2	2	2	2	2
3	3	3	3	3	3	3	3	3	3	3	3	3	3
4	4	4	4	4	4	4	4	4	4	4	4	4	4
5	5	5	5	5	5	5	5	5	5	5	5	5	5
6	6	6	6	6	6	6	6	6	6	6	6	6	6
7	7	7	7	7	7	7	7	7	7	7	7	7	7
8	8	8	8	8	8	8	8	8	8	8	8	8	8
9	9	9	9	9	9	9	9	9	9	9	9	9	9
10	10	10	10	10	10	10	10	10	10	10	10	10	10
11	11	11	11	11	11	11	11	11	11	11	11	11	11
12	12	12	12	12	12	12	12	12	12	12	12	12	12
13	13	13	13	13	13	13	13	13	13	13	13	13	13
14	14	14	14	14	14	14	14	14	14	14	14	14	14
15	15	15	15	15	15	15	15	15	15	15	15	15	15
16	16	16	16	16	16	16	16	16	16	16	16	16	16
17	17	17	17	17	17	17	17	17	17	17	17	17	17
18	18	18	18	18	18	18	18	18	18	18	18	18	18
19	19	19	19	19	19	19	19	19	19	19	19	19	19
20	20	20	20	20	20	20	20	20	20	20	20	20	20
21	21	21	21	21	21	21	21	21	21	21	21	21	21
22	22	22	22	22	22	22	22	22	22	22	22	22	22
23	23	23	23	23	23	23	23	23	23	23	23	23	23
24	24	24	24	24	24	24	24	24	24	24	24	24	24
25	25	25	25	25	25	25	25	25	25	25	25	25	25
26	26	26	26	26	26	26	26	26	26	26	26	26	26
27	27	27	27	27	27	27	27	27	27	27	27	27	27
28	28	28	28	28	28	28	28	28	28	28	28	28	28
29	29	29	29	29	29	29	29	29	29	29	29	29	29
30	30	30	30	30	30	30	30	30	30	30	30	30	30
31	31	31	31	31	31	31	31	31	31	31	31	31	31
32	32	32	32	32	32	32	32	32	32	32	32	32	32
33	33	33	33	33	33	33	33	33	33	33	33	33	33
34	34	34	34	34	34	34	34	34	34	34	34	34	34
35	35	35	35	35	35	35	35	35	35	35	35	35	35
36	36	36	36	36	36	36	36	36	36	36	36	36	36
37	37	37	37	37	37	37	37	37	37	37	37	37	37
38	38	38	38	38	38	38	38	38	38	38	38	38	38
39	39	39	39	39	39	39	39	39	39	39	39	39	39
40	40	40	40	40	40	40	40	40	40	40	40	40	40
41	41	41	41	41	41	41	41	41	41	41	41	41	41
42	42	42	42	42	42	42	42	42	42	42	42	42	42
43	43	43	43	43	43	43	43	43	43	43	43	43	43
44	44	44	44	44	44	44	44	44	44	44	44	44	44
45	45	45	45	45	45	45	45	45	45	45	45	45	45
46	46	46	46	46	46	46	46	46	46	46	46	46	46
47	47	47	47	47	47	47	47	47	47	47	47	47	47
48	48	48	48	48	48	48	48	48	48	48	48	48	48
49	49	49	49	49	49	49	49	49	49	49	49	49	49
50	50	50	50	50	50	50	50	50	50	50	50	50	50
51	51	51	51	51	51	51	51	51	51	51	51	51	51
52	52	52	52	52	52	52	52	52	52	52	52	52	52
53	53	53	53	53	53	53	53	53	53	53	53	53	53
54	54	54	54	54	54	54	54	54	54	54	54	54	54
55	55	55	55	55	55	55	55	55	55	55	55	55	55
56	56	56	56	56	56	56	56	56	56	56	56	56	56
57	57	57	57	57	57	57	57	57	57	57	57	57	57
58	58	58	58	58	58	58	58	58	58	58	58	58	58
59	59	59	59	59	59	59	59	59	59	59	59	59	59
60	60	60	60	60	60	60	60	60	60	60	60	60	60
61	61	61	61	61	61	61	61	61	61	61	61	61	61
62	62	62	62	62	62	62	62	62	62	62	62	62	62
63	63	63	63	63	63	63	63	63	63	63	63	63	63
64	64	64	64	64	64	64	64	64	64	64	64	64	64
65	65	65	65	65	65	65	65	65	65	65	65	65	65
66	66	66	66	66	66	66	66	66	66	66	66	66	66
67	67	67	67	67	67	67	67	67	67	67	67	67	67
68	68	68	68	68	68	68	68	68	68	68	68	68	68
69	69	69	69	69	69	69	69	69	69	69	69	69	69
70	70	70	70	70	70	70	70	70	70	70	70	70	70
71	71	71	71	71	71	71	71	71	71	71	71	71	71
72	72	72	72	72	72	72	72	72	72	72	72	72	72
73	73	73	73	73	73	73	73	73	73	73	73	73	73
74	74	74	74	74	74	74	74	74	74	74	74	74	74
75	75	75	75	75	75	75	75	75	75	75	75	75	75
76	76	76	76	76	76	76	76	76	76	76	76	76	76
77	77	77	77	77	77	77	77	77	77	77	77	77	77
78	78	78	78	78	78	78	78	78	78	78	78	78	78
79	79	79	79	79	79	79	79	79	79	79	79	79	79
80	80	80	80	80	80	80	80	80	80	80	80	80	80
81	81	81	81	81	81	81	81	81	81	81	81	81	81
82	82	82	82	82	82	82	82	82	82	82	82	82	82
83	83	83	83	83	83	83	83	83	83	83	83	83	83
84	84	84	84	84	84	84	84	84	84	84	84	84	84
85	85	85	85	85	85	85	85	85	85	85	85	85	85
86	86	86	86	86	86	86	86	86	86	86	86	86	86
87	87	87	87	87	87	87	87	87	87	87	87	87	87
88	88	88	88	88	88	88	88	88	88	88	88	88	88
89	89	89	89	89	89	89	89	89	89	89	89	89	89
90	90	90	90	90	90	90	90	90	90	90	90	90	90
91	91	91	91	91	91	91	91	91	91	91	91	91	91
92	92	92	92	92	92	92	92	92	92	92	92	92	92
93	93	93	93	93	93	93	93	93	93	93	93	93	93
94	94	94	94	94	94	94	94	94	94	94	94	94	94
95	95	95	95	95	95	95	95	95	95	95	95	95	95
96	96	96	96	96	96	96	96	96	96	96	96	96	96
97	97	97	97	97	97	97	97	97	97	97	97	97	97
98	98	98	98	98	98	98	98	98	98	98	98	98	98
99	99	99	99	99	99	99	99	99	99	99	99	99	99
100	100	100	100	100	100	100	100	100	100	100	100	100	100

(approval BHRA)

Legend: P = president of the VR VP = vice president of the VR Del = delegate to the VR M = member of the VR S = secretary CL = company management	VR = administrative board Liq = liquidator GD = general director D = director VD = vice director Dir = board of directors	OF = business manager b.a = limited to HS = headquarters ZN = branch ZB = authorized signatory	EU = individual signature KU = joint signature EP = individual proxy KP = joint proxy Stv = representative
--	--	--	--

E = Entry, C = Change, D = Deletion

E	C	D	Personal Data	Function	Signature Type
1		20	GHEZAN, Dr. Dieter, of Niederdorf, in Pfaffen	member	joint signature of two
1		7	KOMMIS, Dr. Ivan, of Oberwil BL, in Oberwil BL	member	joint signature of two
1		2m	LOMELI, Dr. Andre, French citizen, in Wollesley (Massachusetts, USA)	member	joint signature of two
1		2	BAUERHART, Dr. Richard, of Birsingen in Herfingen	director	joint signature of two
1		7	STO-GOPPEL & Lybrand AG in Basel	auditors	joint signature of two
1		7m	LAMBERT, Dr. Andre, French citizen, in Wollesley (Massachusetts, USA)	president	joint signature of two
4		5	MELILL, Dr. Blommet, French citizen, in Uffheim (D)	director	joint signature of two
5		10m	ISLAM, Dr. Khalid, British and Italian citizen, in Reinach BL	director	joint signature of two
7		10m	LAMBERT, Dr. Andre, of Basel, in Neuheim	president	joint signature of two
9		32	Pfizer Waterhouse Coopers AG, in Basel (CH 270.9.000.074-6)	auditors	joint signature of two
9		10m	WELTEN, Harry, of Sauron, in Basel	director	joint signature of two
10		32m	LAMBERT, Dr. Andre, of Basel, in Zug	president	joint signature of two
10		32	FERNANDEZ, Dr. Maria, of Birsingen, in Birsingen	vice-president	joint signature of two
10		24m	ISLAM, Dr. Khalid, British and Italian citizen, in Reinach BL	delegate	joint signature of two
10		17	MALLET, Andre, of Geneva, in Thierwil	member	no signatory power
10		20	PERSSON, Dr. Magnus, Swedish citizen, in Urdingo (SE)	member	no signatory power
10		19m	WELTEN, Harry, of Sauron, in Basel	D and S (not a member)	joint signature of two
11		31	KLEINMANN, Prof. Dr. Axel, German citizen, in Hans-Walden (D)	member	no signatory power
16		21m	GRANITZ, Sven-Knud, Danish citizen, in Birkhof (D)	member	no signatory power

E	C	D	Personal Data	Function	Signature Type
19		32	Stokker, Martin, of Basel and Bleienbach, in Wittenwil		no-signatory-power
20		28m	Rath, Dr. Jürgen, German citizen, in Vandoeuvres	member	joint-signature-of-two
20		21m	Groiveldinger, Guy, citizen of Luxembourg, in Rheinfelden		no-signatory-power
	21	24	Carlson, Dr. Søren Knud, Danish citizen, in Birkedal (DK)	member	no-signatory-power
	21	28	Chen, Dr. Nam Hai, citizen of Singapore, in New York (US)	member	joint-signature-of-two
21		31	Hedwary, Dr. Paul, of Suhr in Biel-Bienne		joint-signature-of-two
	21	31	Laesere, Dr. Sergio, Italian citizen, in Reimsch-Gb		joint-signature-of-two
	21	26m	Groiveldinger, Dr. Guy, citizen of Luxembourg, in Rheinfelden		no-signatory-power
24		32m	Pettigrew, Michel, Canadian citizen, in Le Grand-Saconnex	member	



## Commercial Register of the Canton of Basel-Landschaft- Main Register

CH-200.3.00.550-0			Evolve Holding SA		Reinach BL		4		
All entries									
B	C	D	Personal Data			Function		Signature Type	
	24	28m	tolani, Dr. Khalid, British and Italian citizen, in Reinach BL			chairman of the CL		joint signature of two	
	26	32	Groth, d'inger, Dr. Guy, citizen of Luxembourg, in Rheinelden			vice-director		joint signature of two	
28	28	30	tolani, Dr. Khalid, British and Italian citizen, in Reinach BL			member		joint signature of two	
	32	32	Schreyer, Simon, of St. Gallen, in Mont-sur-Rolle			member		no-signatory-power	
	28	32	Reiter, Dr. Jorgon, German citizen, in Vorderrueben			chairman of the CL		joint signature of two	
29		31	Reischo, Susanna, of Birschwil, in Allschwil					joint signature of two	
29		32	Wessmann, Sabine, German citizen, in Hofstetten GO					joint signature of two	
32			Schliet, Prof. Dr. Brich, German citizen, in Ottersloft (DE)			president		joint signature of two	
32			Goldsmith, Neil, British citizen, in Delemont			delegate		joint signature of two	
	32		Lamotte, Dr. Andre, of Basel, in Zug			member		joint signature of two	
			Mallot Jacques, French citizen, in Fourqueux (FR)			member		joint signature of two	
		32	Pettigrew, Michel, Canadian citizen, in Le Grand-Sacornex			member		joint signature of two	
32			Saunders, Ingeliso, Danish citizen, in Skorpung (DK)			member		joint signature of two	
32			Triquet, Jean-Philippe, of Chexard-Saint-Martin, in Zurich			member		joint signature of two	
32			Dynnes Hansen, Jakob, Danish citizen, in Basel			director		joint signature of two	
32			Ernst & Young AG, in Basel (CH-2703.012.140-6)			auditors		joint signature of two	

Liestal, December 11, 2007 at 2:33 PM

This extract from the Commercial Register of the Canton is not valid without the original authentication on the left. It contains all of the current entries applicable to this company and any deleted entries. This extract was issued prior to publication in the Swiss Commercial Register Office Gazette and after approval of the last entry by the Confederation Office for the Commercial Register.

Commercial  
Register Office  
of the Canton of  
Basel-  
Landschaft

Authenticated  
Extract

Commercial Registrar  
of the Canton of Basel-Landschaft  
(signature)



## Handelsregister Kanton Basel-Landschaft - Hauptregister

Firmennummer	Nachtragsregister	Eintragung	Löschung	Übertrag von:	Übertrag auf:
CR-280.3.000.990-0	Aktiengesellschaft	28.08.1997			1



Alle Mittragungen

Ref	LS	Firma	Ref	Seite
1		Amplea	1	Münchenerstrasse
2		AMPLEA AG	20	Reinach St.
2 32		(AMPLEA AG) (AMPLEA-AG)		
32		Nyolva Holding SA		
32		(Nyolva Holding AG) (Nyolva Holding LTD)		

Ref	Aktienkapital (CHF)	Liberalisierung (CHF)	Aktien-Stückelung	Ref	Adresse der Firma
1	100'000.-	100'000.-	10'000 Nennkapitalen zu CHF 10.-	1	Bühnenstrasse 36
2	336'000.-	336'000.-	36'000 Nennkapitalen zu CHF 10.- und 36'000 Namensaktien zu CHF 10.- (Vorzugsaktien)	20	4153 Münchenerstrasse 33 4153 Reinach
6	462'350.-	462'350.-	46'235 Nennkapitalen zu CHF 10.- und 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien)		
7	466'600.-	466'600.-	46'660 Nennkapitalen zu CHF 10.- und 36'040 Nennkapitalen zu CHF 10.- (Vorzugsaktien)		
8	1'000'170.-	1'000'170.-	10'001 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B)		
12	1'662'610.-	1'662'610.-	16'626 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
13			55'537 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
14	1'809'115.-	1'809'115.-	18'091 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
15	2'177'850.-	2'177'850.-	21'778 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
18	3'074'391.-	3'074'391.-	30'743 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
22	3'624'391.-	3'624'391.-	36'243 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
23	3'776'640.-	3'776'640.-	37'766 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
25	3'987'030.-	3'987'030.-	39'870 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
27	4'028'820.-	4'028'820.-	40'288 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
32	27'788'118.80	27'788'118.80	277'881 Nennkapitalen zu CHF 10.- 36'135 Nennkapitalen zu CHF 10.- (Vorzugsaktien A) und 55'537 Nennkapitalen zu CHF 10.- (Vorzugsaktien B) und 62'917 Nennkapitalen zu CHF 10.- (Vorzugsaktien C)		
Ref	FS-Kapital (CHF)	Liberalisierung (CHF)	Partizipationsproben		



Ref	LS	Zweck	Ref	Postadresse
1 32		Forschung und Entwicklung von Medikamenten, deren Vermarktung sowie die in diesem Zusammenhang stehenden Aktivitäten.		
32		Zweck der Gesellschaft ist das Halten von Beteiligungen sowie die Forschung und die Entwicklung von Medikamenten, deren Vermarktung sowie die in diesem Zusammenhang stehenden Aktivitäten. Die Gesellschaft kann alle mit ihrem Zweck oder der Anlage ihrer Mittel direkt oder indirekt in Verbindung stehenden Geschäfte vornehmen. Die Gesellschaft kann Zweigniederlassungen im In- und Ausland errichten, sich an anderen Gesellschaften beteiligen oder mit diesen fusionieren. Die Gesellschaft kann Liegenschaften erwerben, halten und verkaufen.		

Mistel, 11.12.2009 16:33

Fortsetzung auf der folgenden Seite 2



## Handelsregister Kanton Basel-Landschaft - Hauptregister

CH-280.3.000.980-0	Evolva Holding SA	Reinach BL	2
--------------------	-------------------	------------	---

## Alle Eintragungen

Sl	Lo	Bemerkungen	Ref	Statutendatum
1	8	Die Mitteilungen der Gesellschaft an die Aktionäre erfolgen schriftlich oder durch Publikation im SBAB.	1	23.07.1997
1		Die Übertragbarkeit der Namensaktien ist nach Massgabe der Statuten beschränkt.	2	23.07.1998
2	3	Die Vorzugsaktien gewähren Vorrechte bezüglich Liquidationserlösen gemäss Statuten.	6	09.12.1999
2	8	Die Vorzugsaktien gewähren Vorrechte bezüglich Liquidationserlösen und Bezug eines Aktien-gewinns.	7	26.06.2000
8	10	Die Mitteilungen der Gesellschaft an die Aktionäre erfolgen durch ein geschriebenes Exemplar.	8	20.09.2000
8	12	Die Vorzugsaktien A- und B-gewähren Vorrechte bezüglich Liquidationserlösen und Bezug eines Aktien-gewinns gemäss Statuten.	12	06.06.2004
12	10	Die Vorzugsaktien A- und B-gewähren Vorrechte bezüglich Liquidationserlösen und Bezug eines Aktien-gewinns gemäss Statuten.	12	06.06.2004
18		Die Mitteilungen der Gesellschaft an die Aktionäre erfolgen durch ein geschriebenes Exemplar.	13	16.07.2004
27		Geschuldete Kapitalerhöhung im Umfang von CHF 220'000.-- und bedingte Kapitalerhöhung im Umfang von CHF 111'610.40.	14	22.09.2004
32		Die Generalversammlung hat mit Beschluss vom 26.11.2009 eine bedingte Kapitalerhöhung sowie eine genehmigte Kapitalerhöhung gemäss aktueller Umschreibung in den Statuten eingeführt.	15	19.10.2004
			17	08.04.2005
			18	09.04.2005
			19	03.05.2005
			20	19.07.2006
			22	22.03.2007
			23	22.03.2007
			24	08.05.2007
			25	10.08.2007
			27	01.04.2008
			28	07.05.2008
			32	26.11.2009
			32	11.12.2009

Sl	Lo	Bemerkungen	Ref	Publikationsorgan
1	2	Sachbeurteilung: Die Gesellschaft beabsichtigt, nach der Gründung ein Patent bezüglich Identifikation und Aufreinigung von Nomenen des bakteriellen Phosphattransfersystems (PTS) als antibakterielle Verbindung bzw. die Rechte und Pflichten aus einem Lizenzvertrag betreffend der Entwicklung der antibakteriellen Verbindung K-1 zum Preis von CHF 100'000.-- zu übernehmen.	1	SBAB
2		Die Gesellschaft übernimmt in Realisierung der bei der Gründung vom 23.07.1997 geäußerten Absicht, ein Patent bezüglich Identifikation und Aufreinigung von Nomenen des bakteriellen Phosphattransfersystems (PTS) als antibakterielle Verbindung bzw. die Rechte und Pflichten aus einem Lizenzvertrag betreffend der Entwicklung der antibakteriellen Verbindung K-1 zum Preis von CHF 100'000.--.		
15		Sachbeurteilung: Die Gesellschaft übernimmt bei der Kapitalerhöhung vom 13.10.2004 gemäss Sacheinlagevertrag vom 08., 11., 12. und 13.10.2004 insgesamt 4'111'503 Namensaktien zu CHF 1.-- der "Omnia A/B", in Kopenhagen (DK), wofür 1'065'030 Namensaktien zu CHF 0.20 (Vorzugsaktien C) ausgegeben werden.		
28		Sachbeurteilung: Die Gesellschaft übernimmt bei der Kapitalerhöhung vom 10.09.2007 gemäss Sacheinlagevertrag vom 10.09.2007 108'751 Namensaktien zu CHF 1.-- und 200'000 Namensaktien A zu CHF 2.-- (Vorzugsaktien) der "TWT Medical Ltd", in Reimsch BL (CH-280.3.000.432-0), zum Preis von CHF 2'030'252.20, wofür 52'820 Namensaktien zu CHF 0.20 ausgegeben und CHF 2'007'699.20 als Agio den Reserven gutgeschrieben werden. Bei Eintritt gewisser Bedingungen werden zusätzliche Zahlungen an die Sacheinleger in der Höhe von maximal CHF 55'000'000.-- fällig.		
32		Sachbeurteilung: Die Gesellschaft übernimmt bei der ordentlichen Kapitalerhöhung vom 11.12.2009 gemäss Sacheinlagevertrag vom 11.12.2009 sämtliche 310'477 Namensaktien zu CHF 20.-- der "Evolva AG", in Allschwil (CH-170.3.027.314-6), wofür 127'836'400 Namensaktien zu CHF 0.20 ausgegeben werden.		



Sl	Lo	Zweigniederlassung	Sl	Lo	Zweigniederlassung	Sl	Lo	Zweigniederlassung	Sl	Lo	Zweigniederlassung

Liestal, 11.12.2009 14:33

Fortsetzung auf der folgenden Seite 3





## Handelsregister Kanton Basel-Landschaft - Hauptregister

CH-250.3.000.580-0	Evulva Holding SA	Reinach BL	4
--------------------	-------------------	------------	---

## Alle Eintragungen

St.	Nr.	Id.	Personalangaben	Funktion	Zeichnungsart
24	28	28	Selwyn, Dr. Philip, britischer und schweizerischer Staatsangehöriger, in Reinach BL	Vorsitzender des GS	KV zu zweien
25	32	32	Graveldinger, Dr. Guy, luxemburgischer Staatsangehöriger, in Hofstetten	Revisor	KV zu zweien
26	30	30	Selwyn, Dr. Philip, britischer und schweizerischer Staatsangehöriger, in Reinach BL	Mitglied	KV zu zweien
27	32	32	Schnee, Elmar, von St. Gallen, in Mont-sur-Rolle	Mitglied	ohne GS
28	32	32	Reuss, Dr. Willy, deutscher Staatsangehöriger, in Wädenswil	Vorsitzender des GS	KV zu zweien
29	31	31	Müller, Heinrich, von Büschwil, in Allschwil		KV zu zweien
30	32	32	Müller, Heinrich, deutsche Staatsangehöriger, in Hofstetten		KV zu zweien
31			Schlick, Prof. Dr. Erich, deutscher Staatsangehöriger, in Otterstadt (DE)	Präsident	KV zu zweien
32			Goldsmith, Phil, britischer Staatsangehöriger, in Dolémont	Delegierter	KV zu zweien
33	32	32	Lamotte, Dr. André, von Basel, in Zug	Mitglied	KV zu zweien
34			Waller, Jacques, französischer Staatsangehöriger, in Pourquaux (ZU)	Mitglied	KV zu zweien
35	32	32	Settigrew, Michel, kanadischer Staatsangehöriger, in Le Grand-Saconnar	Mitglied	KV zu zweien
36			Saunders, Ingelise, dänische Staatsangehörige, in Skovping (DK)	Mitglied	KV zu zweien
37	32	32	Tripet, Jean-Philippe, von Chézard-Saint-Martin, in Zürich	Mitglied	KV zu zweien
38	32	32	Dynnes Hansen, Jakob, dänischer Staatsangehöriger, in Basel	Direktor	KV zu zweien
39	32	32	Ernst & Young AG, in Basel (CH-270.3.012.140-5)	Revisionsstelle	KV zu zweien

Liestal, 11.12.2009 14:33

Dieser Auszug aus dem kantonalen Handelsregister hat ohne die nebenstehende Originalbeglaubigung keine Gültigkeit. Er enthält alle gegenwärtig für diese Firma gültigen Eintragungen sowie allfällige gestrichenen Eintragungen. Dieser Auszug wurde vor Publikation im Schweizerischen Handelsanbalt und nach Genehmigung der letzten Eintragung durch das Eidg. Amt für das Handelsregister ausgestellt.



Beglaubigter

Auszug

Handelsregister des  
Kantons Basel-Landschaft